EUVIMEDEUVIMED entdecken
EditorialKommentar

Federal Trade Commission Oversight of the Pharmaceutical Industry

Amy Kapczynski Jd

JAMA · 2024

DOI: 10.1001/jama.2024.1509 ↗

Kurz gefasst

Editorial in der Zeitschrift JAMA, 2024. Verfasst von Amy Kapczynski Jd. Beteiligte Einrichtung: Yale Law School, New Haven, Connecticut. Hauptthemen laut MEDLINE: Drug Industry, United States Federal Trade Commission, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C. Joseph Ross Daval, JD; Alexander C. Egilman, BA; Ameet Sarpatwari, PhD, JD; Aaron S. Kesselheim, MD, JD, MPH

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryUnited States Federal Trade CommissionDrug CostsHumansGovernment RegulationUnited StatesUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Yale Law School, New Haven, Connecticut.

Zitieren

APA

Kapczynski Jd, A. (2024). Federal Trade Commission Oversight of the Pharmaceutical Industry. JAMA. https://doi.org/10.1001/jama.2024.1509

Vancouver

Kapczynski Jd A. Federal Trade Commission Oversight of the Pharmaceutical Industry. JAMA. 2024. doi:10.1001/jama.2024.1509

BibTeX
@article{KapczynskiJd2024,
  author = {Kapczynski Jd, Amy},
  title = {Federal Trade Commission Oversight of the Pharmaceutical Industry},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.1509}
}
Kostenlos starten →